- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11:59 | ASCO26: In vivo CAR-Ts in the spotlight | ||
| Di | ASCO26: After negative adcomm, AZ builds case for oral SERD | ||
| Di | Abivax slides on phase 3 data in ulcerative colitis | ||
| Di | ASCO26: Symptom-tracking app helps advanced cancer patients | ||
| Di | ASCO26: AZ triplet makes waves in frontline liver cancer | ||
| Mo | CEPI puts $60m behind three Ebola vaccine candidates | ||
| Mo | Servier wagers $2.65bn on Edgewise muscular dystrophy drug | ||
| Mo | ASCO26: Verzenio gives hope of liposarcoma treatment advance | ||
| Mo | DHSC lauds benefits of single patient record ahead of debate | ||
| Mo | ASCO26: Could AL amyloidosis see a new crop of therapies? | ||
| Mo | ASCO26: DNA test could spare breast cancer patients chemo | ||
| Mo | Lilly licenses Hanmi GLP-2 drug in $1.26bn deal | ||
| Fr | ASCO: BMS hails "compelling" phase 3 celmod readout | ||
| Fr | Pharmacy First prescribing expanded to ease GP pressure | ||
| Fr | Review advises against broad NHS prostate cancer screening | ||
| Fr | WHO names three 'priority' Ebola drugs for trials | ||
| Fr | Ahead of ASCO data drop, AZ gets key Imfinzi approval | ||
| Fr | Innovent in line for $10.5bn in Pfizer cancer alliance | ||
| Do | France 'first EU country to cover obesity drugs' | ||
| Do | GSK hails 'unprecedented' cure rates with hep B drug | ||
| Do | EpiWatch app detects major seizures with few false alarms | ||
| Do | November date set for FDA decision on Sanofi's Gaucher drug | ||
| Do | AbbVie's Immunogen buy delivers rare cancer drug approval | ||
| 27.05. | Zuckerberg, Chan's Biohub launches protein 'world model' | ||
| 27.05. | FDA delays verdict on AZ breast cancer drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.